Phase III
The two companies will work closely to harness the abilities of dopamine receptor modulators to help patients living with complex neuropsychiatric conditions.
Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.
AbbVie announced Qulipta hit the mark in its Phase III study by reducing mean monthly migraine days compared to placebo. Learn more about this migraine treatment here.
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
This target date is the latest development in a long series of setbacks that Acadia - and other pharma companies - have experienced getting Alzheimer’s treatments approved.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Pfizer has launched a Phase II/III study to assess its oral antiviral Paxlovid in non-hospitalized symptomatic pediatric patients who are at risk for progression to serious disease.
The XTEND-1 study showed that efanesoctocog alfa met its primary endpoint of clinically meaningful bleed prevention in people ages 12 years and older with severe hemophilia.
The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.
Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.
PRESS RELEASES